Sesen Bio Inc (NASDAQ:SESN) Expected to Announce Earnings of -$0.08 Per Share

Wall Street brokerages expect Sesen Bio Inc (NASDAQ:SESN) to post earnings per share (EPS) of ($0.08) for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Sesen Bio’s earnings, with the highest EPS estimate coming in at ($0.07) and the lowest estimate coming in at ($0.09). Sesen Bio posted earnings per share of ($0.09) during the same quarter last year, which would indicate a positive year-over-year growth rate of 11.1%. The company is scheduled to announce its next quarterly earnings results on Monday, March 2nd.

According to Zacks, analysts expect that Sesen Bio will report full-year earnings of ($0.91) per share for the current financial year, with EPS estimates ranging from ($0.92) to ($0.90). For the next financial year, analysts expect that the company will post earnings of ($0.38) per share, with EPS estimates ranging from ($0.39) to ($0.37). Zacks’ EPS calculations are a mean average based on a survey of analysts that follow Sesen Bio.

Sesen Bio (NASDAQ:SESN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.01).

SESN has been the subject of a number of analyst reports. Zacks Investment Research lowered shares of Sesen Bio from a “buy” rating to a “hold” rating in a research note on Tuesday, October 15th. Laidlaw lowered shares of Sesen Bio from a “buy” rating to a “hold” rating in a research note on Friday, August 9th. Finally, HC Wainwright restated a “buy” rating and set a $2.25 price objective on shares of Sesen Bio in a research note on Wednesday, November 13th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $2.17.

Shares of Sesen Bio stock traded down $0.01 during trading on Wednesday, hitting $1.20. The company’s stock had a trading volume of 1,650,496 shares, compared to its average volume of 2,000,342. The company has a market capitalization of $123.52 million, a PE ratio of -2.18 and a beta of 0.72. Sesen Bio has a 52 week low of $0.66 and a 52 week high of $2.60. The company has a fifty day simple moving average of $1.20 and a two-hundred day simple moving average of $1.34.

A number of large investors have recently added to or reduced their stakes in the business. Cambridge Investment Research Advisors Inc. bought a new stake in Sesen Bio during the 2nd quarter valued at about $31,000. D. E. Shaw & Co. Inc. bought a new stake in Sesen Bio during the 2nd quarter valued at about $32,000. Vanguard Group Inc. increased its stake in Sesen Bio by 0.6% during the 2nd quarter. Vanguard Group Inc. now owns 3,554,563 shares of the company’s stock valued at $5,332,000 after purchasing an additional 22,228 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in Sesen Bio during the 2nd quarter valued at about $37,000. Finally, Jane Street Group LLC bought a new stake in Sesen Bio during the 2nd quarter valued at about $48,000. Institutional investors and hedge funds own 22.49% of the company’s stock.

About Sesen Bio

Sesen Bio, Inc, a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer.

Recommended Story: The components of the Stochastic Momentum Index

Get a free copy of the Zacks research report on Sesen Bio (SESN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sesen Bio (NASDAQ:SESN)

Receive News & Ratings for Sesen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sesen Bio and related companies with MarketBeat.com's FREE daily email newsletter.